Pharmacoeconomics: theory and practice


Kostina E.O., Kulikov A.Y., Serpik V.G., Yagudina R.I. 290

Comparative analysis of the methodology of pharmacoeconomic assessment according to the origin (dated 08.28.2014) and the current (dated 10.29.2018) version of the government degree of the Russian Federation №871

The fifth year in the system of state drug provision at the federal level, the Decree of the Government of the Russian Federation N871 of 08.28.2014 introduced the requirement of pharmacoeconomic evaluation of drugs when they are included in the lists of drugs. At the end of 2018, the second edition of this document was adopted and brought dramatic changes to the rules of pharmacoeconomic evaluation. This fact prompted us to conduct a comparative analysis of the old and new versions of the document from the point of view of pharmacoeconomics in order to retrospectively identify and systematize the shortcomings and advantages of the rules of pharmacoeconomic evaluation given by the original version of the document and prospectively determine to what extent the new version of the Russian Federation Resolution N871 of 28.08. 2014 (ed. From 10.29.2018) managed to overcome the identified problems and whether it contains any new contradictions. The adoption of the first edition of the Decree of the Government of the Russian Federation N871 of 08.28.2014 approved the mandatory status of pharmacoeconomic evaluation when including drugs in the lists. At the same time, practical experience in applying the developed rules for pharmacoeconomic evaluation revealed their imbalance: due to the minimum number of scores received by a drug according to the cost-effectiveness analysis, the probability of including innovative or even modern effective drugs in the lists was very small. The lack of clear requirements for the interpretation of the results of the cost-effectiveness analysis (and the incremental cost- effectiveness analysis), the conduct of the budget impact analysis and the selection of comparative drugs with an unbalanced integral scale led to pharmacoeconomic studies aimed at achieving positive pharmacoeconomic evaluation (preparation of the minimum required number of points on an integrated scale). The new version of the document largely corrected the lack of the first version of the rules, increasing the number of scores awarded by the cost-effectiveness analysis and introducing various scenarios of this analysis method, which undoubtedly should make the new rules more focused on the evaluation of innovative and effective drugs. At the same time, the “country-specific” methodology for assessing the results of the incremental cost-effectiveness analysis was included in the updated rules. It can be predicted with high probability that an insufficiently complete and accurate description of it in Government Decree N871 of August 28, 2014 (as amended on 10.29.2018) will cause discrepancies in the integral scoring of this type of analysis, creating difficulties for all participants in the listing process: for customers of pharmacoeconomic evaluations, researchers, as well as expert organizations. Attention is drawn to the contradictions that arise when evaluating drugs according to the “cost minimization” analysis scenario, in which the required minimum passing score does not provide for the very fact of cost savings on the considered drug, but only the condition that the savings will exceed 20%. Unfortunately, the new version of the document did not solve the problem of the validity of the used gradation of the integral score scale, and moreover, this problem was increased, violating the logic of interpretation of the results of the cost-effectiveness analysis and the cost-effectiveness incremental analysis.

Congress materials

.., .., .., .., .. 218

The use of warfarin and apixaban in the treatment of coronary artery disease, their pharmacological efficacy and economic costs

.., .., .., .., .. 223

Assessment of climatic, geographical and pharmacological features in the treatment of arterial hypertension among residents of the Far North

.., .., Radionov E.O., .. 248

Improving approaches to the organization of medical assistance based on RFID technology

.., Radionov E.O., .. 220

The use of drugs therapy trends in the mobile electronic medical record

Borisova O.., Dzhuparova I.A. 254

The use of rational pharmaceutical management methods of determine the strategic groups of drugs used in the treatment of degenerative joint diseases

Borisova O.., Dzhuparova I.A. 215

Assessment of availability of antiviral drugs included in the list of the minimum range

Gainov V.S., .., .., Lebed R.A., Tikhonov A.V. 226

Standards of consumption (write-off) of dental materials and medical products units and organizations of the ministry of the Russian Federation

Gainov V.S., Golubenko R.A., .., Kostenko N.L., KRASILNIKOV M.S. 227

Modern aspects of the provision of medical property to students in the pre-university educational institutions of the ministry of defense of the Russian Federation

.., Reshetko O.V. 225

Analysis of Saratov pharmaceutical market structure for drugs in cephalgia treatment

.., .., .. 249

Information for the patient for rational use of medicines

Abrashkina E.A., Borisova O.., Dzhuparova I.A., Djuparov A.S. 238

Social stratification patients of the diabetes mellitus

Dolotovskaya P.V., Malinova L.I., Reshetko O.V., .., Furman N.V. 219

Pharmacoepidemiology of antiplatelet drugs in pre-hospital and hospital stages of care for patients with acute myocardial infarction with ST-segment elevation (analysis of real clinical practice)

Dremova N.B. 231

Trend analysis of the indicator of average per capita consumption of medicines on the Russian pharmaceutical market

.., Kononov V.N., .. 226

Justification of the need for standardization of pharmaceutical activity of pharmacy organizations in the conditions of military health care

.., .., Kubaeva M.B. 229

Quantitative and qualitative assessment of the range of anti-asthma medicines available ro Russian consumers

Kabakova T.I., Kalinin I.V. 229

Analysis of prescribing antiretroviral drugs prison health care organizations

Kirilochev O.O., Umerova A.R. 219

Pharmacoepidemiological analysis of combined psychotropic therapy

.., .., .. 225

Evaluation of antihypertensive drugs using cost-effectiveness analysis

klishchenko M.Y., Kuznetsov D.A. 226

Research of social adaptation of pharmaceutical workers

.., Kononov V.N., Miroshnichenko Y.V., Radionov E.O., Stavila A.G., Scherba M.P. 233

Improving the efficiency of resource management of medical assets by means of information support of medical assistance in military healthcare

.. 220

Analysis of the effectiveness insulin delivery in the treatment type 1 diabetes

Kuznetsov D.A. 225

The role of rharmacoeconomics in pharmaceutical providing of economic security

Gainov V.S., Golubenko R.A., Krasheninnikov A.E., Lebed R.A., Radionov E.O., Tihonov A.V. 220

Medical and economic mechanisms for improving drug care in military medical organizations

Ardenova N.N., Levitan A.I., Reshetko O.V., .. 222

Pharmacoepidemiological analysis of rheumatoid arthritis treatment in older patients

.., .., Levitan A.I., .., Reshetko O.V. 217

Analysis of recommended pharmacotherapy in patients after inpatient treatment of chronic obstructive pulmonary disease exacerbation

.., .., Levitan A.I., .., Reshetko O.V. 230

Real practice of chronic obstructive pulmonary disease exacerbation pharmacotherapy in hospital

Levitan A.I., Reshetko O.V., Rizhenkova I.G., .. 253

Analysis of osteoasrthritis pharmacotherapy as a comorbid pathology of the musculoskeletal system in various arthritis

Leushina E.A. 258

Pharmacoeconomic analysis of drug therapy in patients with a stable form of ischemic heart disease at the stationary stage

Leushina E.A. 225

Pharmacoeconomic analysis of medical treatment of stable ischemic disease in practice of local treatment doctor

Zhuneva M.V., Kondratieva D.A., Magdeev R.M., Nemolyaeva E.K. 218

Pharmacoepidemiology of drugs used for the correction of anemia in patients on renal replacement therapy

Karagozyan C.C., Lutsevich K.A., Melkumyan E.H. 213

Analysis of women’s use of combined oral contraceptives using internet-questionnaire

Kostina O.., Lesonen A.S., Markelov U.M. 234

Clinical and economic effectiveness of the use of polymerase chain reactions – Gene xpert technique in diagnostics and treatment of tuberculosis with multiple medicine stability

Kostenko N.L., Kuznetsova e.v., Lebed R.A., Miroshnichenko Y.V., Radionov E.O., Scherba M.P. 220

Assessment of medical technologies in the conditions of military health care: precondinditions and perspectives

Golubenko R.A., Merkulov A.V., Miroshnichenko Y.V., Scherba M.P. 212

Justification of possible forms of organization of assessment of medical technologies in the conditions of military health care

Radionov E.O. 234

Determination of efficiency of application of near infrared spectroscopy technology in military healthcare

Gainov V.S., Kononov V.N., Kostenko N.L., Miroshnichenko Y.V., Radionov E.O. 213

Economic efficiency of implementation of the system of standardizations in military sanatorium-resort organizations activity

Victorova I.B., .., Levchenko V.G., Mymrina A.L. 223

Pharmaceutical safety in secondary respiratory diseases in patient with HIV infection in the hospital setting

Kabakova T.I., Prokopenko V.V. 219

The analysis of efficiency of an enterosorbtion at allergic rhinitis: results of questioning of doctors

Kostenko N.L., Miroshnichenko Y.V., Radionov E.O., Skibo I.A. 230

The role of the farmacoeconomic researches determine of effectiveness of medical psychological-reabilitation for soldiers

Garmashova I.V., Kononov V.N., Lebed R.A., Miroshnichenko Y.V., Radionov E.O., Saushkina A.S. 215

The identification of product range and assessment of the effectiveness of the manufacture of drugs in field conditions during emergencies

Kuznesov D.A., .. 234

Studying the relationship of the consumers to the loan program from the position of marketing security of pharmaceutical organizations

.., .. 213

Pharmaceutical care and anti-nicotine treatment

Reshetko O.V., Smotrova U.N. 222

Characteristics of doctors’ knowledge about prescribing antibiotics for systemic use

Reshetko O.V., Sokolov A.V. 216

Pharmacoepidemiological analysis of antithrombotic therapy of atrial fibrillation in the hospital in 2011-2012 and 2016-2017

Golubenko R.A., Merkulov A.V., Miroshnichenko Y.V., Radionov E.O., Stavila A.G., Tikhonov A.V. 219

Determination of efficiency of application of near infrared spectroscopy technology in military healthcare

Ruziev K.R., Suyunov N.D., Urunova I.I. 217

Study of the drug and its pricing of amlodipine used in the disease, characterized by increased blood pressure

Mirahmedov M.U., Rajabova D.H., Suyunov N.D. 213

Study of viral diseases and anti-virus medicines

Narzikulov K.S., Ruziev K.R., Suyunov N.D. 217

Study of the prevalence of the disease, characterized by elevated blood pressure

Narzikulov K.S., Ruziev K.R., Suyunov N.D. 225

Study of drugs used for diseases, characterized by increased blood pressure and their value

Reshetko O.V., Shirokova I.A. 227

The real practice of antibacterial therapy of gestational pyelonephritis in the hospital

Miroshnichenko Y.V., Scherba M.P. 213

Basic provisions of the model of rational medical support, based on the implementation of insurance principles and mechanisms of interstate interaction

Ganicheva L.M., Yazinina A.V. 215

Statistic analysis of the range of immunobiological preparations and their relationship with the incidence

Balykina Y.E., Globin M.V., Kolbin A.S., Litvinova A.A., Proskurin M.A. 216

Comparative clinical and economic analysis of the outcomes of type 2 diabetes mellitus (type2 diabetes) in the treatment of insulin degludec or glargine U100 (U300) in the basis-bolus insulin therapy mode

Balykina Y.E., Globin M.V., Kolbin A.S., Litvinova A.A., Proskurin M.A. 213

Comporative clinical and economic analysis of the outcomes of type 1 diabetes mellitus (type 1 diabetes) with insulin derludec or glargine U100 (U300)

Kabakova T.I., Umirova A.A. 215

Analysis of consumer demand for medicines for the treatment of community acute pneumonia